BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Is Amarin Corporation PLC (AMRN) GlaxoSmithKline (GSK)'s New Target?


8/2/2012 8:30:43 AM

After the PHASE III results for AMR-101, Amarin shares (AMRN) traded at almost twenty dollars a share amidst the speculation that a major pharmaceutical company would acquire Amarin. When that event failed to occur, the shares dropped in price, briefly touching the high six dollar range. Now, Amarin has received FDA approval for the drug, now known as Vascepa, and many investors are once again pondering the potential suitors for this small pharmaceutical company. Many names have been tossed into the hat, but one that has not received as much talk as I might have suspected is GlaxoSmithKline (GSK).

Read at Seeking Alpha

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->